Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Envarsus 4 mg prolonged-release tablets

Active Ingredient:
tacrolimus monohydrate
Company:  
Chiesi Limited See contact details
ATC code: 
L04AD02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Safety Alert
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Envarsus – prolonged-release tacrolimus tablets

{healthcare_pro_orange} For Healthcare Professionals
Educational materials for the healthcare professional (doctor or pharmacist) Please read the full Summary of Product Characteristics before prescribing Envarsus
{pdf_link}

Envarsus Patient Card

{healthcare_pro_orange} For Healthcare Professionals
Envarsus Prolonged-release tacrolimus tablets Patient Card

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Chiesi Limited
Company image
Address
Chiesi Limited, 333 Styal Road, Manchester, M22 5LG
Telephone
+44 (0) 161 488 5555
Telephone
0800 009 2329
Medical Information e-mail
[email protected]
WWW
http://www.chiesi.uk.com
Product Quality Complaints
[email protected]
Stock Availability
[email protected]
Stock Availability
https://qrco.de/bg07dl
Drug Safety e-mail
[email protected]
Medical Information Direct Line
+44 (0)1748 827 271
Medical Information Website
https://www.chiesimedical.co.uk